B Braun Medical, CeGaT Launch US Company Offering NGS-based Dx Panels | GenomeWeb

NEW YORK (GenomeWeb) – B Braun Medical US and Tuebingen, Germany-based CeGaT today announced the launch of a US company offering next-generation sequencing-based diagnostics.

The new firm called B Braun CeGaT is based in B Braun Medical's headquarters in Bethlehem, Pa. and will offer CeGaT's diagnostic panels for evaluating all the genes that are associated with a patient's phenotype. The technology was launched in 2010 and is being made available in the US with the establishment of B Braun CeGaT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.